Filing Flows › United Therapeutics (UTHR) › R&D spending
United Therapeutics (UTHR) R&D spending by quarter
United Therapeutics' R&D spending was $279M in Q3 2026 (third quarter 2026), +91% from Q2 2026. Over the last 7 quarters it ranged from $128M (Q3 2025) to $279M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $279M | +91% | +119% |
| Q2 2026 | $146M | +6% | +9% |
| Q1 2026 | $138M | -0.9% | -7% |
| Q4 2025 | $140M | +9% | — |
| Q3 2025 | $128M | -5% | — |
| Q2 2025 | $134M | -10% | — |
| Q1 2025 | $149M | — | — |
Q3 2026 at a glance
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
Questions
What is United Therapeutics' R&D spending?
United Therapeutics' R&D spending was $279M in Q3 2026 (third quarter 2026), +91% from Q2 2026.
How has United Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $128M (Q3 2025) to $279M (Q3 2026).